The Role of ITGAM in Systemic Lupus Erythematosus

TAP0307.6: Sub-study of TAP 0307- Enrollment of Normal Controls to Study the Role of ITGAM in Systemic Lupus Erythematosus

NCT01230112•Northwell Health

View on ClinicalTrials.gov

Summary

Study to examine the role of ITGAM molecule in normal control subjects with known genetic variation in the ITGAM gene.

Eligibility

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•males and females, age 18 or older, enrolled in Genotype and Phenotype Registry, in general good health
•Participants who carry the genotype of interest, based on a buccal or blood derived DNA sample

Exclusion Criteria

•History of Systemic Lupus Erythematosus, rheumatoid arthritis, or other autoimmune disease
•History of cancer or lymphoma
•Current use of aspirin, prednisone, or NSAID or any immunosuppressant
•Self reported HIV

Locations (1)

Feinstein Institute for Medical Research

Manhasset, New York, United States

Key Dates

Start Date

December 1, 2009

Primary Completion Date

April 1, 2012

Completion Date

April 1, 2012

Last Updated

July 30, 2013

Enrollment

ACTUAL participants

Conditions

Systemic Lupus Erythematosus

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

NCT06647069

Systemic Lupus Erythematosus (SLE)Rheumatoid Arthritis (RA)

View study

RECRUITINGPHASE1

A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

NCT07371468

Systemic Lupus Erythematosus

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 30, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Role of ITGAM in Systemic Lupus Erythematosus

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus

Alnuctamab for Refractory SLE (LATTE Study)

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases